Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

5 clinical studies listed.

Filters:

Nontuberculous Mycobacterium Infection

Tundra lists 5 Nontuberculous Mycobacterium Infection clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT04294043

IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)

The purpose of this study is to assess the safety and tolerability of two 5-day infusion cycles of IV gallium in adult patients with CF who are infected with NTM. Funding Source - FDA Office of Orphan Products Development (OOPD)

Gender: All

Ages: 18 Years - Any

Updated: 2025-10-01

10 states

Nontuberculous Mycobacterium Infection
ACTIVE NOT RECRUITING

NCT06004037

Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex

The purpose of this study is to evaluate the efficacy and safety of delpazolid add-on therapy in Patients with Refractory Mycobacterium abscessus Complex Pulmonary disease

Gender: All

Ages: 19 Years - Any

Updated: 2025-08-22

Nontuberculous Mycobacterium Infection
Mycobacterium Abscessus Infection
RECRUITING

NCT04921943

Hypertonic Saline for MAC

The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.

Gender: All

Ages: 18 Years - Any

Updated: 2025-08-15

3 states

Nontuberculous Mycobacterial Lung Disease
Nontuberculous Mycobacterium Infection
ENROLLING BY INVITATION

NCT06262282

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in killing the mycobacteria. Individuals who are found to have at least one phage will be offered assistance in pursuing FDA approval for treatment via expanded-access Individual New Drug (IND) for compassionate-use. They will receive phage treatment for 1 year along with their guideline-based antibiotics for NTM. Individuals who are not identified as having a phage match will be followed as they continue to receive guideline based antibiotic therapy for 1 year. All subjects, including those who do not have a phage match will continue to be observed for the duration of the study, or about 1 year.

Gender: All

Ages: 6 Years - Any

Updated: 2025-05-21

16 states

Cystic Fibrosis
Nontuberculous Mycobacterial Lung Disease
Nontuberculous Mycobacterium Infection
+2
RECRUITING

NCT03120481

Controls for Respiratory Diseases

This is the registry of control participants for patients with various respiratory diseases. We screened healthy volunteers who visited Seoul National Hospital Healthcare System Gangnam Center for routine health check-up, and enrolled patients who agree to participate in the study. The participants undergo baseline questionnaires, provide blood specimen and information of the results of health check-up. We will include participants as controls if they have no significant respiratory symptom and no significant radiographic abnormality. The data from this registry will be compared with those from other registry of various respiratory diseases

Gender: All

Ages: 19 Years - 90 Years

Updated: 2017-04-19

1 state

Chronic Obstructive Pulmonary Disease
Asthma
Idiopathic Pulmonary Fibrosis
+3